Doc....totally agree on where a significant investment of funds has gone to manufacturing and automation for commercialization. I also agree on label extensions for other solid tumors once approved is huge opportunity as well. I also agree with Flip on UK commitment of $ for commercial expansion of DCVax manufacturing hub for Europe as noted in Oct 2015.
label extensions are all that are needed once approved
Doc logic, can you clarify what would that entail? I wrestle with this all the time but my current understanding is it would need a confirmatory trial for each label extension or is it more of a pharmacokinetic study in pts with that type of cancer or maybe something in between?